Posted by Defense World Staff on Jul 25th, 2024
Swiss National Bank lifted its position in LifeStance Health Group, Inc. (NASDAQ:LFST – Free Report) by 25.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 186,800 shares of the company’s stock after acquiring an additional 37,800 shares during the period. Swiss National Bank’s holdings in LifeStance Health Group were worth $1,153,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also recently made changes to their positions in the company. Allen Investment Management LLC purchased a new position in LifeStance Health Group in the 1st quarter valued at $79,000. Assetmark Inc. boosted its position in LifeStance Health Group by 21.6% during the fourth quarter. Assetmark Inc. now owns 11,895 shares of the company’s stock worth $93,000 after acquiring an additional 2,114 shares during the last quarter. Stratos Wealth Partners LTD. purchased a new stake in LifeStance Health Group during the 4th quarter valued at about $93,000. SG Americas Securities LLC raised its holdings in LifeStance Health Group by 8.7% in the 1st quarter. SG Americas Securities LLC now owns 44,925 shares of the company’s stock valued at $277,000 after acquiring an additional 3,600 shares during the last quarter. Finally, GSA Capital Partners LLP lifted its stake in LifeStance Health Group by 161.6% in the 1st quarter. GSA Capital Partners LLP now owns 69,492 shares of the company’s stock worth $429,000 after purchasing an additional 42,932 shares in the last quarter. 85.50% of the stock is currently owned by hedge funds and other institutional investors.
LifeStance Health Group Stock Performance
NASDAQ:LFST opened at $5.50 on Thursday. The company’s 50-day moving average is $5.55 and its two-hundred day moving average is $6.20. LifeStance Health Group, Inc. has a 1-year low of $4.64 and a 1-year high of $9.50. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.18 and a quick ratio of 1.18. The firm has a market capitalization of $2.10 billion, a price-to-earnings ratio of -11.46 and a beta of 1.20.
LifeStance Health Group (NASDAQ:LFST – Get Free Report) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.03. The firm had revenue of $300.44 million for the quarter, compared to analysts’ expectations of $299.02 million. LifeStance Health Group had a negative return on equity of 11.92% and a negative net margin of 15.69%. During the same period in the prior year, the firm posted ($0.09) earnings per share. The firm’s quarterly revenue was up 18.9% on a year-over-year basis. Analysts forecast that LifeStance Health Group, Inc. will post -0.26 EPS for the current year.
Wall Street Analysts Forecast Growth
Separately, Morgan Stanley restated an “overweight” rating and issued a $10.00 price target on shares of LifeStance Health Group in a research report on Monday, April 22nd. One analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $8.80.
Check Out Our Latest Report on LifeStance Health Group
Insider Buying and Selling
In other LifeStance Health Group news, insider Paula Cipollone sold 48,278 shares of the company’s stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $7.22, for a total value of $348,567.16. Following the transaction, the insider now owns 239,915 shares of the company’s stock, valued at $1,732,186.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, major shareholder Summit Partners Growth Equity sold 3,802,345 shares of LifeStance Health Group stock in a transaction that occurred on Friday, May 24th. The shares were sold at an average price of $5.89, for a total value of $22,395,812.05. Following the completion of the sale, the insider now owns 41,932,358 shares in the company, valued at approximately $246,981,588.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Paula Cipollone sold 48,278 shares of the company’s stock in a transaction on Monday, May 13th. The stock was sold at an average price of $7.22, for a total value of $348,567.16. Following the transaction, the insider now owns 239,915 shares in the company, valued at $1,732,186.30. The disclosure for this sale can be found here. In the last ninety days, insiders sold 4,087,716 shares of company stock valued at $24,010,444. 6.60% of the stock is currently owned by insiders.
LifeStance Health Group Company Profile
LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.
Further Reading
- Five stocks we like better than LifeStance Health Group
- Are Penny Stocks a Good Fit for Your Portfolio?
- Food Processing Company Stock Gets Fried by Recall: Time to Buy
- Investing in Travel Stocks Benefits
- Entertainment Stock Offers A Rare and Tempting Entry Opportunity
- 5 discounted opportunities for dividend growth investors
- Will China’s Interest Rate Cuts Ignite a Rally for This Stock?
Want to see what other hedge funds are holding LFST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LifeStance Health Group, Inc. (NASDAQ:LFST – Free Report).
Receive News & Ratings for LifeStance Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeStance Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
You might be interested in:
Cadence Bank Given New $35.00 Price Target at Royal Bank of Canada
Cadence Bank Given New $33.00 Price Target at Barclays
Calix Lowered to Sell at StockNews.com
Taylor Morrison Home Given Neutral Rating at Wedbush
Heartland Express Upgraded to Hold at StockNews.com
Sangamo Therapeutics Receives Buy Rating from HC Wainwright